A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Ravulizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors Alexion Pharmaceuticals
- 15 Oct 2019 Planned End Date changed from 1 Jun 2021 to 1 Aug 2022.
- 15 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2020.
- 20 Mar 2018 Status changed from not yet recruiting to recruiting.